GAITHERSBURG, Md., June 1,
2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a
global company advancing protein-based vaccines with its novel
Matrix-M™ adjuvant, today announced that it will participate in the
Jefferies Global Healthcare Conference.
|
Conference
Details:
|
|
|
|
Fireside
Chat
|
|
|
Date:
|
Thursday, June 8,
2023
|
|
Time:
|
9:00 – 9:25 a.m.
Eastern Daylight Time (EDT)
|
|
Location:
|
New York, NY
|
|
Moderator:
|
Roger Song, M.D., CFA,
Equity Research Analyst – Biotechnology
|
|
Novavax
participants:
|
John C. Jacobs,
President and Chief Executive Officer and
Filip Dubovsky, M.D.,
President, Research and Development
|
|
|
|
|
Conference
|
|
|
Event:
|
Investor
Meetings
|
|
Date:
|
Thursday, June 8,
2023
|
|
|
|
Recordings
A replay of the recorded fireside session
will be available through the Events and Presentations page of the
Company's website at ir.novavax.com for 30 days from the date
of the conference.
About Novavax
Novavax, Inc. (Nasdaq: NVAX) promotes
improved health by discovering, developing and commercializing
innovative vaccines to protect against serious infectious diseases.
Novavax, a global company based in Gaithersburg, Md., U.S., offers a
differentiated vaccine platform that combines a recombinant protein
approach, innovative nanoparticle technology and Novavax's patented
Matrix-M adjuvant to enhance the immune response. Focused on the
world's most urgent health challenges, Novavax is currently
evaluating vaccines for COVID, influenza, and COVID and influenza
combined. Please visit novavax.com and LinkedIn for more
information.
Contacts:
Investors
Erika Schultz
240-268-2022
ir@novavax.com
Media
Ali Chartan
240-709-5563
media@novavax.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/novavax-to-participate-in-the-jefferies-global-healthcare-conference-301839681.html
SOURCE Novavax, Inc.